Holen Sie sich die Stockscreener-App
7.13
0.42%
0.03
Handel nachbörslich:
7.12
-0.010
-0.14%
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits
ImmunityBio, Inc. (NASDAQ:IBRX): Are Analysts Optimistic? - Moomoo
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Investors to Connect - ACCESS Newswire
IBRX stock eyes best week since February: Founder highlights new Anktiva-NK cell therapy study - MSN
ImmunityBio | 4: Statement of changes in beneficial ownership of securities-Director Selecky Christobel - Moomoo
ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026 - Insider Monkey
ImmunityBio (IBRX) director awarded 65,600 stock options at $7.25 strike - Stock Titan
ImmunityBio (IBRX) director Wesley Clark receives 65,600 stock options at $7.25 strike - Stock Titan
ImmunityBio (IBRX) director granted 65,600 stock options at $7.25 strike - Stock Titan
Director at ImmunityBio (NASDAQ: IBRX) awarded 65,600 options - Stock Titan
ImmunityBio (IBRX) re-elects full board, ratifies Deloitte as 2026 auditor - Stock Titan
2026-06-09 | Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Stockholders to Inquire about Securities Investigation | NDAQ:IMMP | Press Release - Stockhouse
IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List - Stocktwits
FDA to Review Expanded Use of Cancer Drug - Los Angeles Business Journal
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend - Stocktwits
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ImmunityBio, Inc.: Shareholders Board Members Managers and Company Profile | US45256X1037 - marketscreener.com
ImmunityBio Inc Cash Flow – XETR:26CA - TradingView
ImmunityBio director Simon Barry J. sells $165,305 in stock - Investing.com UK
Director Barry Simon Sells 23,033 Shares of ImmunityBio Inc (IBR - GuruFocus
Immunitybio earnings loom amid Anktiva growth, FDA scrutiny - Investing.com
ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy Now - Yahoo Finance
ImmunityBio director Simon Barry J. sells $165,305 in stock By Investing.com - Investing.com India
ImmunityBio (IBRX) director Simon sells 23,033 shares under Rule 10b5-1 plan - Stock Titan
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug - Stocktwits
IBRX Stock Set To Snap 2 Days Of Losses? Anktiva Back In Focus Ahead Of COVID-Cancer Link Data - Stocktwits
ImmunityBio responds to FDA promotional compliance concerns - Investing.com
ImmunityBio stock rises after FDA compliance response - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
ImmunityBio Advances HPV-Positive Head and Neck Cancer Trial, Setting Up a New Catalyst for IBRX Investors - TipRanks
IBRX: ANKTIVA delivers durable cancer responses, drives global growth, and expands into new indications - TradingView
[144] ImmunityBio, Inc. SEC Filing - Stock Titan
ImmunityBio secures five US patents for Anktiva in bladder cancer - MSN
ImmunityBio ASCO ANKTIVA Data Reframes Lung And Bladder Cancer Outlook - Yahoo Finance
D Boral Capital maintains ImmunityBio (IBRX) buy recommendation - MSN
ImmunityBio Inc stock (US45258J1025): HC Wainwright reiteration follows Nasdaq pullback - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Investors to Inquire about Securities Investigation - ACCESS Newswire
IBRX Reiterates by HC Wainwright -- Price Target Maintained at $15 - GuruFocus
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
IBRX Stock Price, Quote & Chart | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
ImmunityBio (IBIO) Showcases Promising Clinical Data for ANKTIVA at ASCO 2026 - GuruFocus
ImmunityBio presents ANKTIVA data at ASCO meeting By Investing.com - Investing.com Nigeria
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 - The AI Journal
ImmunityBio presents ANKTIVA data at ASCO meeting - Investing.com
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm - Eastern Progress
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ImmunityBio: Anktiva Explained and What Comes Next - The Globe and Mail
IBRX and the BCG Shortage: Deals That Could Expand Demand - Yahoo Finance
IBRX Stock Outlook After Q1 Results and a New FDA Review - Yahoo Finance
0.40%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):